Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces the results of its 2025 annual and special meeting of shareholders (the "Meeting") held virtually today.ITEM 1. ELECTION OF DIRECTORSAt the Meeting, all director nominees listed in the Company's management information circular (the "Circular") dated May 7, 2025, were elected as directors of the Company. Detailed results of the vote by ballot are as follows:DIRECTORVOTE TYPENUMBER O ...

Company Overview - Torex Gold Resources Inc. is an intermediate gold producer based in Canada, focusing on the exploration, development, and operation of its 100% owned Morelos Property, which spans 29,000 hectares in the Guerrero Gold Belt, located 180 kilometers southwest of Mexico City [2][3]. Key Assets - The principal asset of the company is the Morelos Complex, which includes the producing Media Luna Underground, ELG Underground, and ELG Open Pit mines, as well as the development stage EPO Underground Project and a processing plant [3]. Production and Development - Commercial production from the Morelos Complex commenced on April 1, 2016, and an updated Technical Report for the Morelos Complex was released in March 2022 [3]. Strategic Objectives - Torex's strategic objectives include delivering Media Luna to full production, building EPO, optimizing production and costs at Morelos, growing reserves and resources, disciplined growth and capital allocation, attracting top industry talent, and leading in responsible mining [4]. Growth and Diversification - The company aims to realize the full potential of the Morelos Property while seeking opportunities to acquire assets that enable diversification and deliver value to shareholders [4].

Torex Gold Releases 2024 Responsible Gold Mining ReportReport shines a spotlight on continued leadership in responsible miningJune 12, 2025 6:00 AM EDT | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) today released its 2024 Responsible Gold Mining Report (the "Report") titled Building from Strength, the Company's tenth annual dis ...

10x Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.68 indicates a 43.1% upside potential.The mean estimate comprises 14 short-term price targets with a standard deviation of $3.05. While the lowest estimate of $6.50 indicates a 26.6% decline from the current price level, the most optimistic analyst expects t ...

Toronto, Ontario--(Newsfile Corp. - May 26, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces that an amendment to the Company's restricted share unit plan (the "RSU Plan") will be included in the matters to be presented to shareholders at the annual and special meeting of shareholders of Torex scheduled to be held on June 18, 2025 (the "Meeting").The RSU Amendment is being made in response to comments from a proxy voting advisory and corporate governance services firm (the ...

Gene sequencing technology company 10x Genomics (TXG 2.52%) hasn't been having it easy in the past few days on the stock market. A bearish analyst move dampened sentiment on the company, and according to data compiled by S&P Global Market Intelligence its price was down by more than 9% week to date as of early Friday morning.Morgan Stanley makes a cutThat occurred on Monday, when Tejas Savant from white-shoe investment bank Morgan Stanley reduced his 10x Genomics price target to $18 per share, far down from ...

Torex Gold Reports Latest Drilling Results from ELG UndergroundResults continue to indicate high-grade mineralization and the long-term potential of the depositMay 20, 2025 6:00 PM EDT | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide remaining results from the 2024 drilling program and initial results from the ...

Summary of 10X Genomics (TXG) 2025 Conference Call Company Overview - **Company**: 10X Genomics (TXG) - **Date of Conference**: May 13, 2025 Key Points Industry Context - The macroeconomic environment has changed significantly, impacting funding for customers, particularly in U.S. academic and government markets [4][10][12] - There is ongoing uncertainty regarding future funding and budget allocations, leading to cautious spending among customers [10][11][12] Financial Performance - The company reported robust growth in reactions and volumes for Chromium consumables, indicating strong fundamentals despite macro pressures [6][7] - The first quarter guidance was suspended due to uncertainty, but a quarterly guidance was provided with a projected growth of 1% from Q1 to Q2 [13][15] - The company experienced a 22% growth in China, indicating strong international performance [17] Product Development and Market Position - The introduction of new products aimed at lowering the price per reaction has driven growth in the single-cell market [6][38] - The Xenium platform is gaining traction, with customers increasingly recognizing its value alongside single-cell technologies [30][32] - The company is focused on expanding its product offerings and improving customer experience to maintain a competitive edge [44][46] Customer Insights and Trends - Customers are showing a preference for established brands during uncertain budget periods, which benefits 10X Genomics [48] - There is a growing demand for both single-cell and spatial technologies, with customers increasingly seeing them as complementary rather than competitive [30][31] Competitive Landscape - The competitive environment remains challenging, but 10X Genomics believes its product quality and customer service will help retain market share [44][46] - The company is actively addressing pricing concerns to remain competitive while ensuring product value [47][48] Future Outlook - The company is optimistic about the long-term growth potential in the biopharma sector, with plans to enhance commercial infrastructure and focus on routine use of its technologies [58][59][60] - Sustained progress is expected to take time, but there is confidence in achieving growth comparable to academic markets [60] Additional Insights - The company has made significant changes to its sales force, focusing on dedicated teams for biopharma accounts and Xenium instruments [49][50] - Cost-cutting measures were implemented, particularly in R&D, to maintain financial health without undermining sales efforts [52] This summary encapsulates the key insights and developments discussed during the conference call, highlighting the company's performance, market dynamics, and strategic direction.

Core Viewpoint - 10x Genomics (TXG) shares have increased by 14.7% recently, with a mean price target of $14.79 suggesting a potential upside of 55.9% from the current price of $9.49 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $3.79, indicating variability among analysts [2] - The lowest estimate of $11 indicates a 15.9% increase, while the highest estimate suggests a 174% surge to $26 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about TXG's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 14.6%, with five estimates moving higher and no negative revisions [12] - TXG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Core Insights - 10x Genomics reported revenue of $154.88 million for the quarter ended March 2025, reflecting a year-over-year increase of 9.8% and exceeding the Zacks Consensus Estimate of $133.25 million by 16.24% [1] - The company posted an EPS of -$0.36, an improvement from -$0.50 in the same quarter last year, with a surprise of 20.00% compared to the consensus estimate of -$0.45 [1] Revenue Breakdown - Consumables revenue reached $115.36 million, slightly below the average estimate of $115.85 million, marking a year-over-year increase of 4.6% [4] - Instruments revenue was reported at $14.82 million, significantly lower than the average estimate of $17.30 million, representing a year-over-year decline of 41.8% [4] - Chromium instruments generated $5.91 million, compared to the estimated $6.46 million [4] - Services revenue was $7.65 million, exceeding the average estimate of $6.30 million, with a year-over-year increase of 46.7% [4] - Consumables from Chromium totaled $84.11 million, surpassing the average estimate of $82.93 million [4] - Spatial consumables revenue was $31.25 million, slightly below the average estimate of $32.91 million [4] - Spatial instruments revenue was $8.90 million, compared to the estimated $10.85 million [4] Stock Performance - Over the past month, shares of 10x Genomics have declined by 4.2%, while the Zacks S&P 500 composite increased by 11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]